Week 9 - Pathophysiology, Therapeutics, and Resistance Mechanisms of Mycobacteria and Multidrug-Resistant Bacteria

Pathophysiology and Cell Wall Structure of Mycobacteria

• Tuberculosis is an ancient human disease caused by mycobacterial infection. It is a definitive disease of deprivation, disproportionately affecting poor, marginalized, and malnourished populations, where out-of-pocket medical costs frequently induce severe financial hardship or deeper poverty.

• Mycobacteria possess a unique cell envelope that structurally distinguishes them from both Gram-positive bacteria (which have a thick peptidoglycan cell wall) and Gram-negative bacteria.

• The structural architecture of the mycobacterial cell wall consists of four sequential, linked layers (from the internal space outward):

  • Cell Membrane: The innermost lipid bilayer that separates the intracellular space from extracellular fluid.

  • Peptidoglycan Layer: Attached directly to the cell membrane, consisting of cross-linked peptides and sugars forming a structural matrix.

  • Arabinogalactan Layer: A polysaccharide layer attached to the peptidoglycan matrix, composed of copolymerized arabinose and galactose sugars.

  • Mycolic Acids: Unique, extremely long-chain fatty acids covalently linked to the arabinogalactan layer.

• Structural features of Mycolic Acids:

  • They contain extremely long carbon chains ranging from $C_{40}$ to $C_{60}$ carbons in length.

  • Each molecule possesses two hydrocarbon chains.

  • They contain cyclopropane ring moieties in positions where double bonds (alkenes) are typically located in standard biological lipids.

  • The dense, highly structured outer lipid environment formed by mycolic acids creates a highly impermeable barrier that protects mycobacteria against chemical agents and severely restricts drug penetration.

• Human-pathogenic species of Mycobacteria include:

  • Mycobacterium tuberculosis: The causative pathogen of tuberculosis.

  • Mycobacterium leprae: The causative pathogen of leprosy.

• Mycobacteria possess the ability to survive intracellularly within host macrophages following phagocytosis, enabling persistent and ongoing chronic infections.

Transmission, Pathogenesis, and Diagnostics of Tuberculosis

• Transmission Kinetics:

  • Tuberculosis is an airborne infectious disease transmitted via aerosolized droplet nuclei.

  • Droplet nuclei range in size from $1\text{ to }5\text{ }\frac{1}{1000}\text{ mm}$ (1\text{ to }5\text{ }\text{̧}\text{µm}) in diameter.

  • Due to their minimal mass, these fine droplets avoid upper respiratory inertial impaction and penetrate directly into the pulmonary alveoli.

• Global Epidemiology and Clinical Disease Burden:

  • In 2022, approximately $1.3 \times 10^6$ people died from tuberculosis globally.

  • TB was the second leading cause of death from a single infectious agent worldwide in 2022, trailing only COVID-19.

  • Immunocompromised individuals face a significantly heightened risk of developing active TB disease.

  • Regional latency prevalence is high in specific populations; for example, an estimated $40\%$ of the population in India harbors latent Mycobacterium tuberculosis in their lungs without active clinical disease.

  • Approximately $1\text{ in }20$ ($5\%$) to $1\text{ in }10$ ($10\%$) individuals infected with latent TB will progress to active disease during their lifetime.

• Pathogenesis and Granuloma Formation:

  • Active pulmonary TB patients exhale droplets containing viable mycobacteria into the air.

  • Uninfected individuals inhale these droplets, which deposit in the lungs and infect pulmonary epithelial cells.

  • Host dendritic cells and macrophages endocytose the mycobacteria and migrate to local lymph nodes to initiate T-cell priming.

  • Adaptive immune recruitment attracts B cells and T cells back to the site of infection in the lungs.

  • Immune cells surround and wall off the infected epithelial cells and dividing mycobacteria, forming a structural lesion called a granuloma characterized by surrounding tissue calcification.

  • Latent TB vs. Active TB Progression:

  • Latent TB: The immune system successfully contains the mycobacteria within the calcified granuloma. The individual experiences no symptoms and is non-contagious.

  • Active TB: If the immune system fails to contain the infection, mycobacteria divide continuously within the granuloma until the structure fails and bursts. Free bacteria spread into surrounding lung tissue and can disseminate hematogenously to extra-pulmonary organs, including the brain.

  • Active pulmonary TB manifests clinically with chronic cough, fever, night sweats, weight loss, and potentially death. Individuals with active disease are actively contagious.

• Diagnostic Testing Modalities:

  • Imaging: Chest X-rays and CT scans visualize pulmonary granulomas and structural lung lesions. While suggestive, imaging alone cannot establish a definitive diagnosis of active disease.

  • Tuberculin Skin Test (TST): Purified TB antigens are applied intradermally. The development of a delayed-type hypersensitivity skin reaction (induration/wheal) indicates immune cell recognition resulting from active or prior TB exposure.

  • Interferon-Gamma Release Assay (IGRA): Whole blood is incubated with Mycobacterium tuberculosis antigens. Quantitative release of interferon-gamma by sensitized T-cells indicates TB infection.

  • Sputum Smears and Cultures: Used to differentiate disease stages:

  • Active TB: Positive TST/IGRA, positive sputum culture, and positive sputum smear.

  • Subclinical TB: Positive TST/IGRA, intermittently positive sputum culture, and typically negative sputum smear.

  • Latent TB: Positive TST/IGRA, negative sputum culture, and negative sputum smear.

  • Cleared Infection / Post-Drug Therapy: Negative sputum culture following successful eradication. Full innate immune clearance yields negative diagnostic tests.

First-Line Anti-Tuberculosis Therapeutics

Standard initial therapy for tuberculosis requires a mandatory 6-month regimen utilizing a four-drug cocktail to suppress resistance: Isoniazid, Rifamycin, Pyrazinamide, and Ethambutol. Standard $β$-lactam antibiotics are ineffective against mycobacteria.

• Isoniazid:

  • Chemical Structure: A simple pyridine ring attached to a carboxamide hydrazide moiety ($-\text{C}(=\text{O})\text{NHNH}_2$).

  • Pharmacological Profile: Prodrug requiring enzymatic metabolic activation.

  • Activation Pathway: Oxidized by the mycobacterial catalase-peroxidase enzyme KatG (encoded by the katG gene) to generate a transient, highly reactive isonicotinic acyl radical intermediate.

  • Mechanism of Action: The acyl radical reacts non-enzymatically with $\text{NAD}^+$ to form an isonicotinic acyl-$\text{NAD}$ adduct. This adduct potently inactivates two key enzymes in the fatty acid synthase II (FAS-II) pathway required for mycolic acid biosynthesis:

  1. Acyl carrier protein reductase (InhA).

  2. $\u03B2$-ketoacyl acyl carrier protein synthase (KasA).

  • Resistance Mechanism: Deletions or point mutations within the katG gene, which prevent the enzymatic conversion of the isoniazid prodrug into its active radical intermediate.

• Rifamycin:

  • Chemical Structure: Complex macrocyclic antibiotic.

  • Mechanism of Action: Direct inhibitor of mycobacterial DNA-dependent RNA polymerase. It binds specifically to the $\u03B2$ subunit of the enzyme within the DNA-RNA channel, sterically blocking the extension of the growing RNA transcript.

  • Pharmacokinetics and Drug Interactions:

  • Potent transcriptional inducer of hepatic and intestinal Cytochrome P450 CYP3A4, causing severe drug-drug interactions with co-administered therapeutics cleared by CYP3A4.

  • Induces and modulates P-glycoprotein (P-gp) transport activity, altering the oral absorption of P-gp substrates and increasing efflux of substrate drugs across the blood-brain barrier back into systemic circulation.

  • Resistance Mechanism: Specific point mutations within the rpoB gene, which encodes the $\u03B2$ subunit of bacterial RNA polymerase, decreasing rifamycin binding affinity.

• Pyrazinamide:

  • Chemical Structure: A pyrazine ring (six-membered aromatic ring containing two nitrogen atoms) bearing a carboxamide group.

  • Pharmacological Profile: Prodrug requiring enzymatic conversion.

  • Activation and Accumulation Pathway:

  1. Pyrazinamide diffuses passively into the mycobacterial cytoplasm.

  2. The bacterial amidase enzyme pyrazinamidase (encoded by the pncA gene) hydrolyzes pyrazinamide into its active metabolite, pyrazinoic acid (POA).

  3. POA is actively or passively effluxed into the extracellular environment.

  4. In the acidic extracellular microenvironment (such as inflamed tissue or granulomas), POA becomes protonated into its neutral conjugate acid form ($\text{POAH}$) due to the basic nature of the pyrazine aromatic nitrogens.

  5. Neutral $\text{POAH}$ passively re-enters the mycobacteria, where it ionizes, trapping protons and accumulating inside the cell.

  • Mechanism of Action: Intracellular accumulation of $\text{POAH}$ causes severe membrane disruption, collapses the proton motive force, and directly inhibits fatty acid synthase 1 (FAS-1), halting mycolic acid production.

  • Resistance Mechanism: Loss-of-function mutations in the pncA gene, leading to deficient pyrazinamidase expression and loss of prodrug activation.

• Ethambutol:

  • Chemical Structure: Symmetrical diamine structure featuring two chiral centers and attached butanol side chains; exhibits carbohydrate-like structural properties.

  • Mechanism of Action: Inhibits the enzyme arabinosyltransferase 3, preventing the polymerization of arabinose monomers into the growing arabinogalactan polysaccharide chain. This halts arabinogalactan synthesis, preventing the linkage of mycolic acids to the peptidoglycan wall and compromising structural cell wall integrity.

  • Genetics and Resistance: Arabinosyltransferases are encoded by a three-gene operon consisting of embC, embA, and embB. Resistance is driven by point mutations in the embB gene, which significantly lowers the binding affinity of ethambutol for the arabinosyltransferase 3 protein.

Multidrug-Resistant Organisms and Global Healthcare Threat

• Epidemiology of Antibiotic Resistance:

  • Antimicrobial resistance (AMR) stems from widespread, continuous antibiotic selection pressure, creating population bottlenecks that select for resistant bacterial strains.

  • Healthcare environments (hospitals) represent primary reservoirs for highly resistant infections.

  • In the United States, more than $2 \times 10^6$ people acquire antibiotic-resistant bacterial infections annually.

  • Projections estimate that by the year 2050, antimicrobial resistance will cause approximately $40 \times 10^6$ deaths globally per year unless effective alternative treatments are implemented.

• Multidrug-Resistant Tuberculosis (MDR-TB):

  • Represents a major global public health crisis due to non-responsiveness to standard 6-month first-line regimens.

  • Severe clinical limitations exist for second-line regimens.

  • Advanced vaccine candidates are under active clinical development, including Phase 3 clinical trials co-sponsored by GlaxoSmithKline (Glaxo) and the Bill & Melinda Gates Foundation.

Specific Resistance Mechanisms and Therapeutic Options for Priority Pathogens

Gram-Positive Resistant Pathogens

• Methicillin-Resistant Staphylococcus aureus (MRSA):

  • Causes severe, invasive nosocomial infections in immunocompromised patients.

  • Resistance Mechanism: Acquisition of the mobile genetic element carrying the mecA gene. The mecA gene encodes an altered penicillin-binding protein, PBP2a, which exhibits extremely low binding affinity for virtually all $\u03B2$-lactam antibiotics, including penicillins, cephalosporins, and carbapenems.

  • Effective Therapeutic Options: Vancomycin, clindamycin, trimethoprim, doxycycline, minocycline, linezolid, and daptomycin.

• Vancomycin-Intermediate Staphylococcus aureus (VISA) & Vancomycin-Resistant Staphylococcus aureus (VRSA).

• Vancomycin-Resistant Enterococci (VRE):

  • Causes bacterial endocarditis, bacterial meningitis, and extensive soft tissue infections.

  • Resistance Mechanism: Alteration of the terminal cell wall peptidoglycan precursor. The normal terminal dipeptide $D\text{-alanyl-}\!D\text{-alanine}$ ($D\text{-Ala-}\!D\text{-Ala}$) is enzymatically modified to $D\text{-alanyl-}\!D\text{-lactate}$ ($D\text{-Ala-}\!D\text{-Lac}$).

  • Modification reduces vancomycin's binding affinity by $1000\text{-fold}$ ($10^3\text{-fold}$), rendering therapeutic vancomycin concentrations completely ineffective at blocking cell wall assembly.

  • Effective Therapeutic Options: Daptomycin, linezolid, and tigecycline.

Gram-Negative Resistant Pathogens

• Gram Staining Differentiation:

  • Gram-Positive: Retain primary crystal violet stain due to thick peptidoglycan layers, appearing purple under light microscopy.

  • Gram-Negative: Counterstained by safranin/fuchsin after crystal violet decolorization, appearing red/pink under light microscopy.

• Neisseria gonorrhoeae:

  • Gram-negative diplococcus causing gonorrhea (a sexually transmitted infection).

  • Resistance Mechanisms:

  1. Enzymatic inactivation of antibiotic molecules.

  2. Target site alterations.

  3. Upregulation of active drug efflux pumps to clear drug from the cytoplasm.

  4. Porin protein mutations that decrease outer membrane drug permeability.

  5. Specific mutations in the penA (encoding Penicillin-Binding Protein 2, PBP2) and ponA (encoding Penicillin-Binding Protein 1, PBP1) genes, leading to reduced binding affinity for penicillins.

  • Effective Primary Treatment: Ceftriaxone.

• Carbapenem-Resistant Enterobacteriaceae (CRE):

  • Cause high-mortality community- and hospital-acquired infections, including complicated urinary tract infections, bloodstream infections (bacteremia), and lower respiratory tract infections (pneumonia).

  • Resistance Mechanisms:

  1. Horizontal acquisition of genes encoding carbapenemases—specialized $\u03B2$-lactamase enzymes capable of hydrolyzing the $\u03B2$-lactam core fused to the carbocyclic ring found in carbapenems.

  2. Porin channel modifications leading to reduced drug uptake.

  • Effective Therapeutic Options: Polymyxins, tigecycline, and aminoglycosides.

• Carbapenem-Resistant Acinetobacter (CRA).

• Pseudomonas aeruginosa.

Drug Discovery Initiatives

• Due to critical resistance development, there is an urgent global necessity for novel antimicrobial drug discovery.

• Academic and industrial drug screening initiatives exist to evaluate synthesized chemical libraries against microbial pathogen panels.

• The Open Drug Discovery Initiative (historically operated by GlaxoWellcome at Griffith University in Australia) provides open-access screening of synthetic chemical compounds against pathogenic microorganisms free of charge to identify novel antimicrobial leads.